Company Overview - Optimi Health Corp. is a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, specifically focusing on psilocybin and MDMA for mental health therapies [6]. - The company operates two 10,000-square-foot facilities in British Columbia, producing validated MDMA and botanical psilocybin products [6]. Recent Developments - Optimi has announced the export of its GMP-manufactured 5 mg psilocybin capsules to Australia for treating patients with treatment-resistant depression (TRD) under the Authorised Prescriber Scheme [1][2]. - This shipment marks Optimi's second finished drug product supplied to Australia, following the earlier supply of 40 mg and 60 mg MDMA capsules for post-traumatic stress disorder (PTSD) [2]. Product Details - The 5 mg psilocybin capsules are now available to patients in Australia suffering from TRD, with the potential for reimbursement by the Department of Veterans' Affairs (DVA) for eligible patients [3]. - Optimi's psilocybin drug product is manufactured under a Health Canada-issued Drug Establishment Licence, allowing for pharmaceutical-grade production and international export for prescription use [4]. Clinical and Regulatory Framework - Treatment outcomes for patients using psilocybin-assisted therapy in Australia are being tracked through a national patient registry in collaboration with the Australian National University (ANU) [4]. - The company emphasizes its control over the full production lifecycle, including cultivation, extraction, encapsulation, and packaging, ensuring consistency and quality in its products [3].